I've been meaning to blog about the following for a while, and it came up in one of the past posts, but here is some information on an exciting new trial for the use of Truvada as a prophylactic measure for HIV transmission:
Recently (week of November 23rd), I read/heard on www.newyorktimes.com and NPR about a recent trial that was conducted using Truvada (a two drug combination nucleoside reverse transcriptase inhibitor) prophylactically. The article itself (on NEJM.org) gives a 44% increase in protection from HIV infection with the prophylactic use of Truvada. The other sources, where I originally heard this news, quoted other percentages, ranging from 44% to 90% efficacy, depending on the subject's reported pill use, as well as laboratory results of measured blood medication levels. I haven't had time to read the article as carefully as I would like to in order to try and discern these numbers for myself (woohoo, winter break!), but it seems like this prophylactic use of an NRTI could be promising...check out the articles below when you have time.
http://www.npr.org/blogs/health/2010/11/23/131536422/pill-cuts-hiv-infection-risk-significantly-for-a-price
http://www.nytimes.com/2010/11/24/health/research/24aids.html?_r=1&ref=research
Grant, R.M., Lama J.R., Anderson P.L., et al. (2010 November 23). Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. The New England Journal of Medicine 10 (1056). Retrieved 13 December 2010 from http://www.nejm.org/doi/full/10.1056/NEJMoa1011205#t=articleTop
No comments:
Post a Comment